flammation, and bronchial hyperresponsiveBackground -Prostaglandin (PG) D 2 is a ness. The airways obstruction is due to smooth potent bronchoconstrictor mediator and muscle contraction, and to airway oedema and is found, together with leukotriene (LT) mucus hypersecretion caused by inflammation. D 4 , in bronchoalveolar lavage fluid during Inflammatory mediators including prostathe early response to allergen challenge in glandin D 2 (PGD 2 ) have been implicated in asthmatic subjects. The potency of PGD 2 these processes.
constricting dose of LTD 4 increases metha-weeks. Bronchial responsiveness to PGD 2 was determined 45 minutes after inhalation of either choline responsiveness for up to two weeks. 18 Inhaled LTE 4 increases histamine respons-placebo or 200 g oxitropium bromide (Boehringer Ingelheim Ltd, Bracknell, UK) as two iveness in asthmatics for up to one week, 19 and LTC 4 enhances the immediate bron-puffs from a metered dose inhaler in a randomised, double blind, crossover fashion. The choconstriction induced by PGD 2 and histamine in asthmatics, 20 although the effects seen percentage inhibition of PGD 2 induced bronchoconstriction by oxitropium bromide was are small. The mechanisms of these interactions have not been fully elucidated.
calculated at the highest concentration of PGD 2 given on the placebo day, as the difference In this study we wished to investigate the potency of PGD 2 as a bronchoconstrictor in between the maximum falls in sGaw after oxitropium and placebo (measured as % change normal subjects and to examine the contribution of cholinergic mechanisms to this. We from baseline), divided by the maximum fall after placebo (%). also aimed to discover whether atopic nonasthmatic subjects showed any differences in response from non-atopic subjects, and to examine the effect of pretreatment with LTD 4 on     4   2  airway responsiveness to PGD 2 . We therefore investigated the bronchoconstrictor potency of Six normal subjects (four men) of mean (SE) age 25.2 (1.7) years were recruited. Subjects PGD 2 in six atopic non-asthmatic and six nonatopic normal subjects, the effect of an anti-initially attended the laboratory on two occasions for measurement of bronchial recholinergic agent, oxitropium bromide, on PGD 2 induced bronchoconstriction in eight sponsiveness to methacholine and LTD 4 . They returned for three further visits, separated by subjects, and the interaction of LTD 4 with PGD 2 responsiveness in six normal subjects.
at least two weeks, when bronchial responsiveness to PGD 2 was measured after pretreatment with either 0.9% saline or nonbronchoconstricting concentrations of methaMethods  choline or LTD 4 , and again six hours after pretreatment. Pretreatments were given in a All subjects were non-smokers with no history of respiratory disease and were not studied randomised, double blind, crossover fashion.
Repeat non-bronchoconstricting doses of within six weeks of a respiratory tract infection. Atopic non-asthmatic subjects had a positive LTD 4 , methacholine, or saline alone were given to three separate subjects to assess cumulative skin prick test (>3 mm) to two or more of a battery of nine common allergens. Caffeine-or effects. theophylline-containing food and drinks were withheld for 12 hours before each study day. Informed consent was obtained from all sub-   Baseline lung function assessment was perjects, and the studies were approved by King's College Hospital ethics committee.
formed in all subjects. The forced expiratory volume in one second (FEV 1 ) was measured (mean of three values) using a dry wedge bellows spirometer (Vitalograph Ltd, Bucks,UK).     2  -    -  Specific airways conductance (sGaw) (mean of 16 values) was measured in an automatic Six normal subjects (two men) of mean (SE) age 25.7 (2.4) years and six atopic non-asth-pressure-flow plethysmograph (Gould 2800 Autobox, Sensormedics, Salford, UK). Flow matic subjects (three men) of mean (SE) age 23.8 (1.7) years took part in the study. Bron-at 30% of vital capacity above residual volume (V max 30 ) (mean of five values) was obtained chial responsiveness to histamine and to PGD 2 was measured on two occasions at least two from partial expiratory flow volume manoeuvres using a rolling seal spirometer (P K weeks apart in a double blind, randomised, crossover fashion. The potency ratio for PGD 2 Morgan Ltd, Gillingham, UK) attached to a differentiator (P K Morgan) and analysed by relative to histamine was calculated as the geometric mean of individually determined ratios computer (Amstrad PC2086) using software developed by Mr K Allen (Medical Physics of PC 35 sGaw histamine to PC 35 sGaw PGD 2 . The duration of PGD 2 induced broncho-Department, King's College Hospital). constriction was defined as the time taken for specific airways conductance (sGaw) to return to within 10% of control values. The re-   Bronchial responsiveness was measured using peatability of histamine and PGD 2 challenges was assessed on two occasions at least two a modification of a standard protocol. 21 Responsiveness was defined as the provocation weeks apart in two groups of five subjects. Baseline lung function tests were not sigbreathing from a Wright nebuliser, driven by nificantly different (p>0.05) between study air at 8 l/min for two minutes. The calibre of days in either the normal or atopic non-asththe airways was monitored by measurements matic subjects. PGD 2 was tolerated well, of sGaw (mean of eight values) at one and six although initial concentrations caused a sigminutes and V max 30 (mean of two values) at nificant cough in all subjects. Inhaled PGD 2 three and eight minutes after inhalation to caused bronchoconstriction in both normal and provide control measurements. Increasing conatopic non-asthmatic subjects. In normal subcentrations of agonist were inhaled in the same jects bronchoconstriction was more clearly apmanner as diluent and the response expressed parent as falls in sGaw than in V max 30 , which as a percentage of the mean control values for remained above 70% of control values in all sGaw and V max 30 . Log 10 dose-response curves subjects, and thus PC 30 V max 30 could not be were constructed and PC 35 sGaw and V max 30 calculated. Compared with normal subjects, obtained by linear interpolation. If V max 30 fell atopic non-asthmatic subjects were, on average, by less than 30%, PC 30 V max 30 was obtained 4.29-fold (95% CI 0.78 to 11.59) more reby extrapolation provided that PC 30 V max 30 was sponsive to PGD 2 (p=0.031); however, the reached within the next doubling dilution, and 3.01-fold (95% CI 1.11 to 16.56) greater his-PC 35 sGaw was taken as the maximum contamine responsiveness seen in the atopic noncentration of PGD 2 if sGaw had not fallen by asthmatic group was not significantly different 35% at this point.
from that in the normal subjects (p=0.174). Both normal and atopic non-asthmatic subjects were more responsive to PGD 2 than to hist-  ,  amine (table 1) , with PGD 2 being 17.8 (95%   4 CI 9.62 to 38.9) and 25.4 (95% CI 15.5 to From initial dose-response curves to metha-41.8) times, respectively, more potent (geocholine and LTD 4 the highest concentration of metric mean) than histamine when PC 35 sGaw each agonist causing a fall in sGaw of less was measured. There was no significant differthan 10% from control was established. On ence in potency compared with histamine besubsequent study days the initial PGD 2 chaltween the two groups (p=0.295). lenge was performed, with each concentration
The correlation between airway responsof PGD 2 being immediately preceded by a iveness to inhaled histamine with that to PGD 2 two minute inhalation of either saline or in normal and atopic non-asthmatic subjects the previously determined non-bronchoconis shown in fig 1. The combined correlation stricting concentration of methacholine or coefficient for PC 35 sGaw histamine with LTD 4 .
PC 35 sGaw PGD 2 in normal and atopic nonasthmatic subjects was highly significant (r= 0.917, p<0.001, n=12). Atopic non-asthmatic   Provocation concentrations were log trans-subjects (n=5) took significantly longer to recover from PGD 2 induced bronchoconstriction formed before analysis by Mann-Whitney or were given at 12 minute intervals, which was the of the baseline value at all time points.
There was no difference in baseline lung function between the three study days or be-(mean (95% CI) 27 (16.8 to 37.2) minutes) tween first and second challenges (p>0.05), than normal subjects (16 (12.7 to 19.3) min-except the FEV 1 at challenge 1 on the methautes; n=6, p=0.034; fig 2) , although there choline study day was significantly higher than was no difference in the degree of broncho-at challenge 1 on the saline study day (p= constriction (measured as maximum fall in 0.036). PGD 2 responsiveness was not altered sGaw) induced by PGD 2 between the two by pretreatment with saline, with no significant groups (p=0.10). Recovery time of one atopic difference between challenges 1 and 2 (p= non-asthmatic subject could not be recorded 0.59; fig 3) . Pre-inhalation of LTD 4 caused a due to a technical problem with the body ple-mean (95% CI) increase in PGD 2 responsthysmograph. Both histamine and PGD 2 chal-iveness of 4.6-fold (0.6 to 36.7) compared with lenges were reproducible in the five subjects saline, but this was not significant (p=0.142). tested, with the geometric mean (95% CI) After six hours bronchial responsiveness had PC 35 sGaw on the two test days being 38.3 mM recovered, being significantly lower at challenge (20.0 to 73.6) and 39.5 mM (27.3 to 57.1) 2 than at challenge 1 (p=0.036). However, for histamine, and 1.8 mM (0.8 to 4.1) and pre-inhalation of methacholine also produced 2.8 mM (0.8 to 9.9) for PGD 2 , although the a non-significant 2.4 (0.7 to 8.1)-fold increase coefficient of repeatability could not be cal-in responsiveness at challenge 1 (p=0.142). culated for this number of subjects.
At six hours there was no significant difference in PGD 2 responsiveness between the three treatment groups (p>0.05).     2   There was no significant difference (p>0.05) in baseline lung function tests between study days. Inhaled oxitropium bromide (200 g) produced significant bronchodilation, causing mean (95% CI) increases from baseline in FEV 1 choline, and saline from a Wright's nebuliser group.bmj.com on April 4, 2017 -Published by http://thorax.bmj.com/ Downloaded from Discussion the airways. In asthmatic subjects a 79% inhibition of PGD 2 induced bronchoconstriction The results show that PGD 2 is a potent bronchoconstrictor in atopic non-asthmatic by ipratropium bromide has been reported. 14 Thus, in normal subjects cholinergic mediation and normal subjects, being 25 times and 18 times more potent than histamine, respectively. of PGD 2 induced bronchoconstriction may play a relatively smaller part than in asthmatic There was a positive linear correlation between histamine and PGD 2 responsiveness when subjects. It is unlikely that the reduction in bronchoconstriction was due to functional atopic non-asthmatic and normal subjects were considered together, in agreement with pre-antagonism as it has been shown that bronchodilation produced by cholinergic agents vious studies which have shown that asthmatic subjects who are hyperresponsive to histamine does not affect responsiveness to inhaled bronchoconstrictors 29 ; however, the data were and methacholine are also hyperresponsive to PGD 2 .
12 Both PGD 2 and histamine challenges standardised as percentage baseline to overcome the effect of bronchodilation. were reproducible in the five normal subjects tested. PGD 2 repeatability is reported as being
There are methodological problems when investigating the interaction of inhaled meless than that for histamine or LTD 4 in asthmatic subjects, 13 which may reflect the greater diators. Different investigators have chosen different techniques, making comparisons belability of bronchial responsiveness in asthmatic subjects. The potency of PGD 2 compared with tween studies difficult. We were unable to demonstrate any significant interaction of inhaled histamine (18 times in normal subjects) is similar on a molar basis to that described for sub-bronchoconstricting doses of LTD 4 or methacholine on PGD 2 responsiveness in norasthmatic subjects (17.8-32.4). [10] [11] [12] Atopic non-asthmatic subjects were 3.01 mal subjects. LTD 4 produced a 4.6-fold shift in the PGD 2 dose-response curve which failed times and 4.29 times more responsive to histamine and PGD 2 , respectively, than normal to reach significance (p=0.142) compared with saline pretreatment, but this is similar in magsubjects. Although none of the atopic nonasthmatic subjects had any history of res-nitude to the significant sevenfold increase in PGF 2 responsiveness seen in asthmatic subpiratory symptoms, other allergic diseases were not excluded. The increased bronchial re-jects pretreated with a non-bronchoconstricting dose of LTD 4 . 17 However, the latter study essponsiveness seen in this group agrees with the increased bronchial responsiveness seen in tablished dose-response curves to PGF 2 over a period of days to avoid the multiphasic doseatopic subjects from a random population 22 and in asthmatics who show bronchial hyper-response characteristics of this prostaglandin, and there may have been changes in the rereactivity to various stimuli including histamine, 21 prostaglandins, 10 and leukotrienes. 23 sponsiveness of the asthmatic subjects during this period. Since mediators would be released Atopic subjects without asthma share, to a lesser extent, some of the features of bronchial simultaneously in vivo, we used a method whereby each concentration of PGD 2 , as well mucosal inflammation observed in subjects with asthma, including mast cell degranulation, as the diluent, was immediately preceded by inhalation of a non-bronchoconstricting coneosinophil activation, and collagen deposition in the basement membrane; 24 these subclinical centration of the pretreatment. It is possible that this method results in increased smooth features may result in a degree of bronchial responsiveness in atopic non-asthmatic sub-muscle tone undetectable by the relatively insensitive measurements of airways conjects. Despite similar baseline lung function tests and a similar degree of broncho-ductance. However, it has been shown that, while LTC 4 and methacholine do increase the constriction following inhalation of PGD 2 , atopic non-asthmatic subjects took significantly baseline contractile state of isolated human airway, they do not, unlike other mediators, longer for sGaw to return to baseline. This may reflect the increased peripheral broncho-increase methacholine sensitivity of the tissue. 30 We controlled for possible physiological constriction induced in this group as detected by changes in V max 30 .
interactions by measuring the effect of nonbronchoconstricting concentrations of metha-PGD 2 causes bronchoconstriction of human airway smooth muscle both by direct mech-choline on PGD 2 responsiveness. While responsiveness was increased in comparison with anisms, acting via the thromboxane receptor, 25 26 and by cholinergically mediated mech-saline pretreatment, the effect was less than that seen following pretreatment with LTD 4 , anisms. Oxitropium bromide is an anticholinergic agent which acts as a potent which suggests that LTD 4 may have slightly increased PGD 2 responsiveness. These changes bronchodilator in both normal and asthmatic subjects.
27 28 We showed a significant increase did not reach significance, possibly because of the relatively few subjects studied, and the in all lung function parameters measured, with sGaw, FEV 1 and V max 30 increasing by 82.1%, possibility of a false negative result cannot be excluded. 3.75%, and 34.8%, respectively, following inhalation of 200 g oxitropium. Oxitropium
The role of prostanoids such as PGD 2 in allergic asthma is unclear. Although mast cell caused a mean 37.5% inhibition of PGD 2 induced bronchoconstriction, shifting the dose-derived prostanoids are generated during bronchoconstrictor responses to allergen, nonresponse curve to the right in six out of eight subjects. It is not clear why in two of the specific cyclo-oxygenase (COX) inhibitors lack significant therapeutic benefit, and may even subjects there was no inhibition, but these subjects did bronchodilate after inhaling oxi-exacerbate asthmatic symptoms, 31-33 probably due to concomitant inhibition of the synthesis tropium, suggesting that the drug had reached 
